JP2022525435A5 - - Google Patents
Info
- Publication number
- JP2022525435A5 JP2022525435A5 JP2021559648A JP2021559648A JP2022525435A5 JP 2022525435 A5 JP2022525435 A5 JP 2022525435A5 JP 2021559648 A JP2021559648 A JP 2021559648A JP 2021559648 A JP2021559648 A JP 2021559648A JP 2022525435 A5 JP2022525435 A5 JP 2022525435A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962831123P | 2019-04-08 | 2019-04-08 | |
| US62/831,123 | 2019-04-08 | ||
| PCT/US2020/027071 WO2020210232A1 (en) | 2019-04-08 | 2020-04-07 | Cd19 antibodies and methods of using the same |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022525435A JP2022525435A (ja) | 2022-05-13 |
| JP2022525435A5 true JP2022525435A5 (https=) | 2023-04-13 |
| JPWO2020210232A5 JPWO2020210232A5 (https=) | 2023-04-13 |
| JP7730295B2 JP7730295B2 (ja) | 2025-08-27 |
Family
ID=72751761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021559648A Active JP7730295B2 (ja) | 2019-04-08 | 2020-04-07 | Ｃｄ１９抗体およびこれを使用する方法 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP3953385A4 (https=) |
| JP (1) | JP7730295B2 (https=) |
| KR (1) | KR20220006065A (https=) |
| CN (1) | CN114341176A (https=) |
| AU (1) | AU2020270888A1 (https=) |
| CA (1) | CA3136251A1 (https=) |
| IL (1) | IL287039A (https=) |
| WO (1) | WO2020210232A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12590148B2 (en) | 2018-11-26 | 2026-03-31 | Nkarta, Inc. | Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy |
| AU2020232691B2 (en) | 2019-03-05 | 2023-06-29 | Nkarta, Inc. | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| IL322315A (en) | 2019-05-14 | 2025-09-01 | Provention Bio Inc | Methods and preparations for preventing type 1 diabetes |
| AU2021287998B2 (en) | 2020-06-11 | 2026-03-12 | Benaroya Research Institute At Virginia Mason | Methods and compositions for preventing type 1 diabetes |
| LT4269444T (lt) | 2020-08-14 | 2024-09-25 | GammaDelta Therapeutics Limited | Daugiaspecifiniai anti-tcr kintamos delta 1 antikūnai |
| CA3214628A1 (en) * | 2021-04-06 | 2022-10-13 | Memorial Sloan-Kettering Cancer Center | Combination therapy with dexamethasone and tumor-specific t cell engaging multi-specific antibodies for treating cancer |
| US12565529B2 (en) | 2021-05-24 | 2026-03-03 | Provention Bio, Inc. | Methods for treating type 1 diabetes |
| JP2024546804A (ja) * | 2021-12-15 | 2024-12-26 | ワイ－マブス セラピューティクス， インコーポレイテッド | Ｓａｄａ複合体を含む製剤 |
| CN119350497A (zh) * | 2023-07-24 | 2025-01-24 | 星尘生物科技(上海)有限公司 | 人源化抗cd19单链可变区片段及其用途 |
| AU2024359838A1 (en) * | 2023-10-13 | 2026-04-23 | Suzhou Ribo Life Science Co., Ltd. | Conjugate, drug conjugate and composition, and preparation method and use |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2398829A2 (en) * | 2009-02-23 | 2011-12-28 | Glenmark Pharmaceuticals S.A. | Humanized antibodies that bind to cd19 and their uses |
| AU2013302696B9 (en) * | 2012-08-14 | 2018-08-09 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
| US20160326249A1 (en) * | 2014-01-15 | 2016-11-10 | Zymeworks Inc. | Bi-specific cd3 and cd19 antigen-binding constructs |
| EA201790719A1 (ru) * | 2014-09-26 | 2017-07-31 | Макродженикс, Инк. | Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения |
| EA039859B1 (ru) * | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| CN110267982B (zh) * | 2016-10-19 | 2024-02-23 | 斯克利普斯研究所 | 具有人源化靶向部分和/或经过优化的嵌合抗原受体相互作用结构域的嵌合抗原受体效应细胞开关以及其用途 |
| SG10201912400VA (en) * | 2017-04-24 | 2020-02-27 | Kite Pharma Inc | Humanized antigen-binding domains against cd19 and methods of use |
| AU2018337142B2 (en) * | 2017-09-22 | 2025-07-03 | Wuxi Biologics Ireland Limited. | Novel bispecific CD3/CD19 polypeptide complexes |
| US11555072B2 (en) * | 2017-09-23 | 2023-01-17 | Memorial Sloan Kettering Cancer Center | A33 antibody compositions and methods of using the same in radioimmunotherapy |
-
2020
- 2020-04-07 JP JP2021559648A patent/JP7730295B2/ja active Active
- 2020-04-07 CA CA3136251A patent/CA3136251A1/en active Pending
- 2020-04-07 EP EP20788168.1A patent/EP3953385A4/en active Pending
- 2020-04-07 CN CN202080041527.2A patent/CN114341176A/zh active Pending
- 2020-04-07 WO PCT/US2020/027071 patent/WO2020210232A1/en not_active Ceased
- 2020-04-07 KR KR1020217036014A patent/KR20220006065A/ko active Pending
- 2020-04-07 AU AU2020270888A patent/AU2020270888A1/en active Pending
-
2021
- 2021-10-06 IL IL287039A patent/IL287039A/en unknown